~~<i id='4E5EB400C8'><strike id='4E5EB400C8'><tt id='4E5EB400C8'><pre id='4E5EB400C8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：entertainment 2025-09-28 01:30:38 - browse：59599

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Review: 'Barbie' will hit you like a shot in the heart

leisure time

explore

hotspot

explore

Wikipedia

leisure time

AlexBrandon/APThefederalgovernmentissuingtoblockaproposedhospitaldealinNorthCarolina,allegingitwould

WSS

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

FTC sues over Novant Health acquisition of two N.C. hospitals

AbbVie dramatically boosts its spending on lobbying

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Humana’s losses in Medicare Advantage tank its stock

Pancreatic cancer early detection could be helped by AI

entertainment

fashion

leisure time

Medical leaders decry Supreme Court decision on affirmative action

10 reasons why health care startups fail

Drug repurposing or repositioning? The language matters

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Walensky prepares to leave CDC — and Congress — behind

Pancreatic cancer early detection could be helped by AI

The high cost of giving birth even with insurance

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Dobbs anniversary: the lost opportunity of abortion as health care

Artificial intelligence advances fuel industry trying to preserve loved ones after death

explore

Why Medicare shouldn’t cover every FDA

FDA official pushes for dedicated emerging pathogens team

Investment in vaccine development is lagging, report finds

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

FDA official pushes for dedicated emerging pathogens team

Body of missing toddler recovered in Delaware River days after flood: Police

hotspot

explore

Wikipedia

leisure time